Drug Trial Radar · NCT00968942
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Last checked: Nov 19, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Aug 2009
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Revance Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 31, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
Conditions
- Lateral Canthal Lines
- Crow's Feet
- Facial Wrinkles
Interventions
Botulinum Toxin Type ADrug
RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
PlaceboDrug
Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line-Rest Severity Scale of the LCA at Baseline compared to Week 8; incidence of treatment emergent AEsTime frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Research Institute, LLC.
Coral Gables, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.